Abzena is a life science group with headquarters in the UK, and chemistry and manufacturing sites in the US. Abzena’s complimentary services and technologies in chemistry, biology and manufacturing, are applied to the selection, development and manufacture of better biopharmaceuticals.
Abzena works with most of the top 20 biopharmaceutical companies and academic groups all over the world and is focused on enabling the development of better treatments for patients. Abzena’s technologies have enabled many of its customers to progress products (ABZENA inside), through to clinical development.
Abzena was created through the incorporation of Antitope, PacificGMP, PolyTherics and The Chemistry Research Solution (TCRS); all of whom now trade as Abzena. Abzena’s technologies and services are provided across its three sites as follows:
Cambridge, UK (Babraham Research Campus), is the main location of our immunology, protein engineering, bioassays, bioanalytics, cell line development and bioconjugation activities. It is Abzena’s global headquarters; housing our commercial, finance and investor relations teams.
San Diego, CA, USA is home to Abzena’s GMP biopharmaceutical manufacturing plant for Phase I and II clinical trials. Cell banking, process development, batch analysis, QC release and regulatory assistance are all provided at this site for both WAVE and single-use bioreactors.
Abzena’s team in Bristol, PA, USA has a strong background in synthetic organic chemistry and expertise in bioconjugation; providing research chemistry, antibody drug conjugate (ADC) services and manufacture of GMP reagents. The company’s manufacturing capabilities in Bristol is being expanded to enable the manufacture of bioconjugates to GMP standards.
Alacrita is life science consulting for a networked age. You can expect the caliber and capabilities of a top-ranked consulting firm, but you'll find a difference in our expertise. We've built our team carefully, hand-picking only those consultants with deep domain knowledge and senior business experience. With more than 200 successful client assignments each year, we're proving what's possible for commercial life sciences in a new era of opportunity.
Albumedix is a science-driven, biotechnology company focused on enabling the creation of superior biopharmaceuticals utilizing our albumin-based drug enhancing technologies. We partner with excellence to improve therapies for people with serious diseases. We are proud to be recognized as the world leader in recombinant human albumin with products and technologies used in clinical and marketed drugs by pharmaceutical companies worldwide. Headquartered in Nottingham, England with more than 80 people all committed to improving patient quality of life. We are just as passionate about albumin and albumin-enabled therapies today as we were when we started 30 years ago.
Almac Discovery is a research driven drug discovery company dedicated to the development of novel and innovative approaches to the treatment of diseases of unmet need (including oncology and CNS), by applying a target class approach. The Almac Discovery business model is to develop preclinical stage assets which are then licenced to pharmaceutical or biotech partners for further development. We also look to collaborate with partners to apply our medicinal chemistry and translational biology expertise to targets of mutual interest. Key research themes include deubiquitinase enzymes and protein drug conjugates.
The Almac Group is an established contract development and manufacturing organisation that provides the most unique range of integrated drug development services available to the pharmaceutical & biotech industry.
We are a privately owned organisation that has organically grown over 50 years and now employs in excess of 5,000 high skilled personnel. Almac is headquartered in Craigavon, Northern Ireland with 17 global facilities across Europe, USA and Asia.
Our quality, innovation and efficiency are testament to the fact that over 600 companies worldwide trust Almac for their Chemical, Pharmaceutical and Clinical Development needs.
Addressing the increasing pressure for Biopharma companies to bring their clinical candidates through their pipeline faster, more efficiently and at a lower cost, Almac provides an integrated CMC service, bridging the gap between drug substance and drug product development.
As an established provider of both drug substance (advanced intermediates and Active Pharmaceutical Ingredients – small molecules and peptides) and drug product development services, and by offering these within an integrated package, our client partners are assured of scientific continuity from a dedicated project team, resulting in significant savings in both time and costs.
AMS Advanced Medical Services
Since 1997 AMS has been a competent partner to the pharmaceutical and healthcare industry service providers in the business areas of Clinical Research.
As an experienced CRO (Contract Research Organization), AMS offers 360 degree customer support in Clinical Trials for phase I – IV as well as for NIS (Non Interventional Trials). Our services include Project Management, Monitoring, Data Entry, Data Management, Biostatistics, Pharmacovigilance/Clinical Safety and Medical Writing as well as Quality Management, including the conduction of Audits and provides support in Regulatory Affairs and Market Authorization. Read more about Clinical Research.
Aptus Clinical is a specialist UK- based oncology clinical research organisation which helps life science companies to optimise their clinical development strategies and effectively transform promising molecules into valued medicines.
What makes Aptus Clinical different is our flexibility – our clients benefit from our network of highly experienced and skilled experts from all technical disciplines, but only pay for what they need, when they need it. Our scientists have global expertise in all aspects of drug development so no challenge is too great, and being highly professional, they integrate seamlessly into a client organisation. This gives our clients all the benefits of an in-house clinical department, but at a significantly lower cost. In addition, our well-established relationships with some of the world’s leading experimental cancer centres, access to large patient populations and flexible arrangements to support optimal project delivery are just a few of the benefits to be gained from working with Aptus Clinical.
Whether you need one-off consultancy support, clinical SOP implementation, expert medical or scientific input on a short or long term basis, or a full trial programme, we’d love to hear from you.
Arcinova is a UK based Contract Research and Development Organisation (CRDO) operating from a 15,000m2 site which has benefited from more than 36 years of investment as a key research and development centre. We provide the pharmaceutical industry with a comprehensive range of services, backed by extensive scientific expertise and strong practical capabilities.
We work to enhance the health and wellbeing of society by helping companies to develop life changing medicines and take them to market quickly, effectively and efficiently.
Our focus is on API process research, the development, validation and application of analytical, microbiological and materials science spectroscopic methodologies, scale-up and early phase clinical product manufacturing. We provide non-clinical and clinical 14C, API, drug product, bioanalysis, regulatory and consulting services.
Our mission at Arcinova is to delight our life sciences customers by satisfying their contract research, development and manufacturing needs with agility, innovation, seamless teamwork and best value delivery.
Astex Pharmaceuticals, Inc. is an international, NASDAQ-listed (ASTX) pharmaceutical company dedicated to the discovery and development of novel therapeutics with a focus on oncology.
Athena Market Access Solutions
Founded in 2016 Athena Market Access Solutions specialises in providing pricing and reimbursement related solutions to organisations in the life sciences industry.
The company is run by Maximilian Lebmeier who has over a decade experience in Global, European and UK/Irish market access roles in the pharmaceutical industry. He has worked on over 130 health technology assessments (HTAs) in a wide range of disease areas including rheumatology, dermatology, cardiology, hepatology, transplantation, infectious diseases, and oncology. Besides of his company duties he has worked intensively with industry associations on market access and HTA related activities.
Athena’s services stretch throughout the lifecycle of a product from payer and reimbursement input into clinical development, early health economics and outcomes research and pricing activities alongside clinical trials and regulatory processes, the preparation of reimbursement submissions, the navigation of pricing and reimbursement procedures, input into clinical guidelines, market access and competitive pipeline and portfolio reviews, training and strategic consultancy.
Athena Market Access Solutions Ltd. is co‐organiser of the ‘Kendal Collaboration’, a group of small businesses and independent professionals with expertise in all aspects of health economics and outcomes research.
Athena’s customers include biotechnology companies, pharmaceutical companies, as well as a consultancies.